Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's...
Covered in this story
What has happened since
- Alaska Air Group is down 7.7% since this was published, 7 days ago.
- Rogers Corp is down 6.4% since this was published, 7 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ROG.SW yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Roche Holding →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.